ImmuCell Corporation — Q2 2015 Form 10-Q
Business context and period: Unaudited results for the three and six months ended June 30, 2015, compared with the corresponding 2014 periods. ImmuCell develops and sells animal-health products for dairy and beef cattle. First Defense and related products are its primary sales driver; Mast Out, a Nisin-based mastitis treatment, remains in development.
Financial performance and condition
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Product sales | $1.960 million | $1.540 million | $5.062 million | $3.621 million |
| Gross margin | $1.131 million; 58% | $879,000; 57% | $2.981 million; 59% | $2.028 million; 56% |
| Operating income (loss) | $214,000 | ($459,000) | $1.034 million | ($446,000) |
| Net income (loss) | $94,000 | ($295,000) | $573,000 | ($308,000) |
| Diluted earnings (loss) per share | $0.03 | ($0.10) | $0.18 | ($0.10) |
- Six-month operating cash flow was $1.518 million, versus $330,000 in 2014. Capital expenditures were $1.434 million, versus $313,000.
- Cash, cash equivalents and short-term investments totaled $3.909 million at June 30, 2015. Working capital was approximately $5.052 million; total assets were $11.242 million.
- Bank debt was approximately $798,000, including $80,000 current and $718,000 long-term. The $500,000 revolving credit line was unused; the company reported compliance with debt covenants.
- Property, plant and equipment, net, rose to $4.816 million from $3.838 million at year-end 2014, principally reflecting facility and equipment investment. Stockholders’ equity was $9.904 million.
Material changes and management commentary
- Sales increased 27% year over year in Q2 and 40% for the first half. First Defense and related products accounted for 91% of Q2 sales and 94% of first-half sales. Management cited strong demand, higher sales and marketing investment, product pricing, and favorable market conditions as contributors.
- Demand exceeded production capacity: orders backlog was approximately $1.452 million at June 30, about 99% First Defense orders. Management is expanding capacity, with equipment investments expected to be completed by Q1 2016.
- First-half product development expense fell to $602,000 from $1.355 million, mainly reflecting reduced Mast Out development spending compared with 2014. Sales and marketing expense increased 29% and administrative expense increased 12% year over year for the first half.
- Management believed existing resources, together with product-sale gross margin, were sufficient for working capital and operations for at least the next 12 months. It stated that it expected First Defense sales growth and recent profitability to continue, subject to production constraints; no specific revenue or earnings guidance was provided.
Outlook, risks and unusual items
- Mast Out commercialization remains subject to regulatory approval, manufacturing readiness and financing. The FDA’s Human Food Safety section was anticipated around mid-2016; the company’s goal was to submit the Drug Substance portion of the Chemistry, Manufacturing and Controls section in the first half of 2016. The company no longer projected a date for final NADA approval.
- Commercial-scale Nisin production was estimated to require approximately $13 million, potentially less for a smaller facility; the company said it did not presently have the capital to fund this alone. A possible in-house sterile-filling facility was estimated at approximately $1 million because of concerns about its contract manufacturer, Norbrook. Financing, partnering, regulatory and timing outcomes remain uncertain.
- Subsequent to quarter-end, ImmuCell paid $23,800 for an option on nearby land for a potential commercial-scale Nisin plant; the option expires December 31, 2015. As of June 30, it had also committed approximately $546,000 to capital expenditures, $402,000 to inventory production and $158,000 to other obligations.
- Key risks include reliance on First Defense and a small number of distributors, backlog-related lost sales, manufacturing and raw-material constraints, competition, product and regulatory risks, and uncertainty in dairy and beef industry economics. Two distributors represented 63% of first-half sales. Management also noted milk prices had declined from 2014 highs.
- Income tax expense was $449,000 for the first half, or 44% of pretax income. The filing reports no legal proceedings and no material change in internal controls; management assessed disclosure controls as effective.
Most important facts for investors to verify
- Whether expanded manufacturing capacity clears the $1.452 million backlog without customer losses or margin deterioration.
- Whether strong First Defense demand and sales growth persist as dairy-market conditions and competitor supply change.
- Progress, timing and costs of Mast Out regulatory submissions, Norbrook alternatives, commercial-scale manufacturing, and any required financing or partnership.
- Cash use for capital investment and inventory, debt covenant compliance, and the company’s stated ability to fund operations for at least 12 months.
- Exposure to major distributors and the realizability of deferred tax assets, which depends partly on future taxable income.